

Metal-free synthesis of 4-(methylthio)isoxazoles with acetylenic oximes and dimethyl(methylthio)sulfonium tetrafluoroborate (DMTSM)

Chengqun Chen* and Zihan Deng

*Department of Chemical Engineering, Fuzhou University Zhicheng College, Fuzhou, P.R. of China*Email: chenchq03@yeah.net

Received mm-dd-yyyy


Accepted mm-dd-yyyy

Published on line mm-dd-yyyy

Dates to be inserted by editorial office

Abstract



An efficient protocol for the synthesis of 4-(methylthio)isoxazoles, by way of the reaction of differentially functionalized acetylenic oximes with dimethyl(methylthio)sulfonium tetrafluoroborate (DMTSM) under mild, metal-free conditions is described and affords the products in moderate to good yields.

**Keywords:** 4-(Methylthio)isoxazole, acetylenic oxime, DMTSM, metal-free

Introduction


As well-known heterocycles, the isoxazole skeleton acts as a key structural framework and pharmacophore, showing diverse biological activities and serving as important privileged architectures in materials science and pharmaceuticals¹⁻³. Sulfur serves as a ubiquitous constituent in biologically active natural products and medicinal molecules^{4, 5}. Moreover, the substitution of heterocyclic rings with sulfenylated derivatives represents a valuable strategy to modulate substituent trajectories, thereby optimizing complementarity and fitting within the ligand-binding pocket during drug design⁶.

The increasing importance of substituted isoxazoles has promoted the development of new synthetic methods. In the past years, numerous approaches to construct functionalized isoxazole derivatives have been reported^{2, 7}; however, the synthetic pathway towards 4-sulfenyl isoxazoles remains relatively underexplored. A classic and representative synthetic approach for 4-sulfenyl isoxazoles involves the reaction of thiosulfonates or disulfides with 4-isoxazolyl anions, which are generated in situ under strong basic conditions at low temperature (Scheme 1, eq 1).^{8, 9}



X = F, Cl, Br, I, B, SeR, SR

This work



Scheme 1. Different methods for the synthesis of 4-sulfenyl isoxazoles

Building on Larock's pioneering work¹⁰ in the synthesis of 4-iodo isoxazoles via electrophilic cyclization of 2-alkyn-1-one O-methyloximes, electrophilic cyclization of oximes using diverse electrophiles has emerged as a robust protocol for constructing 4-functionalized isoxazoles (Scheme 1, eq 2).¹¹⁻¹⁶ This approach is distinguished by its readily available starting materials, operational efficiency, and exceptional regioselectivity. Specifically, electrophilic sulfenylation of 2-alkyn-1-one O-methyloximes with N-sulfanylsuccinimides or disulfides as electrophiles enables the synthesis of 4-sulfenyl isoxazoles under mild reaction conditions, expanding the scope of this methodology to sulfur-containing heterocycles.¹⁶


Dimethyl(methylthio)sulfonium trifluoromethanesulfonate (DMTSM) stands out as a remarkable electrophilic methylthiolating reagent, offering unique advantages including safety, crystallinity, and ease of

handling¹⁷⁻¹⁹. In recent years, the application of dimethyl(methylthio)sulfonium salts has been investigated in direct alkythiolation²⁰, cycloaddition reactions²¹⁻²³, and C–C bond formation²⁴. Herein, we describe a novel and practical approach for the synthesis of 4-(methylthio)isoxazole from acetylenic oximes and DMTSM under ambient temperature conditions.

Results and Discussion

The initial study commenced by adding 1, 3-diphenylprop-2-yn-1-one oxime and DMTSM to acetonitrile, and the substrate mixture was stirred at ambient temperature under an air atmosphere. After 12 hours of reaction, the target compound 4-(methylthio)-3, 5-diphenylisoxazole **3a** was successfully synthesized with a yield of 33%. To enhance the yield of this transformation, the influence factors of solvents, reaction temperature, base, and catalysts were successively investigated (Table 1).

Table 1. Optimization of Reaction Conditions^a



Entry	Solvent	Temp (°C)	Base	catalyst	Yield (%) ^b
1	MeCN	r.t.	None	-	33
2	DCM	r.t.	None	-	42
3	DCE	r.t.	None	-	38
4	THF	r.t.	None	-	15
5	Dioxane	r.t.	None	-	8
6	DCM	40	None	-	35
7	DCM	55	None	-	30
8	DCM	70	None	-	14
9	DCM	r.t.	AcONa	-	23
10	DCM	r.t.	tBuOK	-	28
11	DCM	r.t.	Na ₂ CO ₃	-	67
12	DCM	r.t.	K ₂ CO ₃	-	74
13	DCM	r.t.	K ₂ CO ₃	CuI	73
14	DCM	r.t.	K ₂ CO ₃	Cu(OAc) ₂	71
15	DCM	r.t.	K ₂ CO ₃	FeCl ₃	72

^a Reaction conditions: **1a** (0.5 mmol), **DMTSM** (0.6 mmol), base (0.75 mmol), catalyst(0.05 mmol) and solvent (2 mL) under air for 12 h.

^b Isolated yields.


DCM =dichloromethane, DCE = dichloroethane, THF =tetrahydrofuran.

An initial solvent screening was performed to evaluate dichloromethane (DCM), dioxane, 1,2-dichloroethane (DCE), and tetrahydrofuran (THF) as reaction media (Table 1, entries 2–5). Reactions were conducted at room temperature without the addition of base. Notably, dichloromethane (DCM) proved to be the optimal solvent, furnishing the desired product in 42% yield—outperforming other tested media. 1, 2-

For R² being benzene or substituted benzene rings, satisfactory yields were achieved. Notably, para-substituted benzene rings with electron-donating groups (-CH₃, -OCH₃) afforded yields of 75% and 77% (Table 2, **3b-3c**), respectively, whereas the presence of electron-withdrawing groups (-F, -Cl, -Br, -NO₂) on the benzene ring led to a moderate decrease in yields (Table 2, **3d-3h**). Heterocyclic or aliphatic substituents (R²) led to a notable drop in yields (Table 2, **3i-3j**), with methyl and n-butyl groups yielding merely 32% and 35% (Table 2, **3k-3l**), respectively. This suggests that aromatic systems are more favorable for the reaction than aliphatic or heterocyclic counterparts.

When R¹ is a para-substituted phenyl group or naphthyl ring, the reaction affords comparable yields (Table 2, **3m-3t**). Noteworthy, electron-withdrawing substituents like fluoro and nitro cause slight yield reductions to 64% and 65%, respectively. Similar to the trend observed for R¹, the yields decline appreciably when R² is a heterocycle or alkyl substituent (Table 2, **3u-3v**). When both R¹ and R² are p-tolyl or p-methoxyphenyl groups, the reaction also affords good yields (Table 2, **3w-3x**).


To investigate the reaction mechanism, several control experiments were conducted. First, butylated hydroxytoluene (BHT) and 2, 2, 6, 6-Tetramethylpiperidin-1-oxyl (TEMPO) were used as a radical inhibitor in the reaction (Scheme 2, **a-b**), and no significant effect on the isolated yield was observed. When 1,3-diphenylprop-2-yn-1-one O-methyl oxime was used as the substrate in the reaction with **2** under standard conditions, the desired product **3a** was not obtained (Scheme 2, **c**).



Scheme 2. Control Experiments

Based on these results, the reaction mechanism was proposed as follows: the sulfonium group transfer from DMTSM to 1, 3-diphenylprop-2-yn-1-one oxime generates the intermediate episulfonium ion (I), Subsequently,

the formation of the cyclic intermediate (II) was achieved through the intramolecular cyclization reaction. Ultimately, the anticipated product was generated through deprotonation.



Scheme 3. Plausible reaction mechanism for the hydrolysis reaction

Conclusions

In summary, we herein describe a straightforward and efficient protocol for the synthesis of 4-(methylthio)isoxazoles through the reaction of acetylenic oximes with dimethyl(methylthio)sulfonium tetrafluoroborate (DMTSM) under mild, metal-free conditions. This transformation accommodates a wide array of functional groups on the aromatic ring, yielding the corresponding products in moderate to good yields.

Experimental Section

General procedure for the synthesis of 4-(methylthio)isoxazole. At room temperature, to a solution of alkyne oxime (0.5mmol, 1 equiv) in CH₂Cl₂ (2 mL), DMTSM (0.6mmol, 1.2 equiv) and K₂CO₃ (0.75mmol, 1.5 equiv) were added into the solvent. The mixture was stirred for 12h (TLC monitored). The reaction mixture was extracted with CH₂Cl₂ after adding the saturated brine. Then the organic phase was combined and dried with anhydrous Na₂SO₄. The solvent was evaporated in vacuo, the crude product was purified by column chromatography, eluting with petroleum ether/ethyl acetate to afford the desired products.

4-(Methylthio)-3,5-diphenylisoxazole(3a).¹⁶ Yellow solid (99mg, 74%); mp 66-68°C. IR(KBr) 3051, 2962, 1624, 1167, 1028cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.24 (dd, *J* 8.4 Hz, *J* 2.0 Hz, 2H), 7.99-7.95 (m, 2H), 7.53-7.46 (m, 6H), 2.11 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 169.9, 164.2, 130.3, 129.8, 128.7, 128.6, 128.4, 127.6, 127.1, 106.6, 19.0. HRMS (ESI) (*m/z*): [M+H]⁺ calcd. for C₁₆H₁₄NOS: 268.0796, found: 268.0791.

4-(Methylthio)-3-phenyl-5-(*p*-tolyl)isoxazole(3b). White solid (105mg, 75%); mp 109-114°C. IR(KBr) 3047, 2958, 1618, 1173, 1017cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.23 (d, *J* 8.8 Hz, 2H), 8.20-8.16 (m, 2H), 7.53-7.49 (m,

3H), 7.21 (d, *J* 8.2 Hz, 2H), 2.82 (s, 3H), 2.13 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 169.9, 163.9, 130.9, 130.2, 129.5, 128.8, 128.6, 127.7, 127.3, 126.7, 105.8, 21.6, 15.4. HRMS (ESI) (*m/z*): [M+H]⁺ calcd. for C₁₇H₁₆NOS: 282.0939, found: 282.0947.

5-(4-Methoxyphenyl)-4-(methylthio)-3-phenylisoxazole(3c).¹⁶ White solid (114mg, 77%); mp 91-95 °C. IR(KBr) 3035, 2837, 1613, 1165, 1014cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.19 (d, *J* 9.2 Hz, 2H), 8.00-7.96 (m, 2H), 7.53-7.50 (m, 3H), 7.04 (d, *J* 8.8 Hz, 2H), 3.89 (s, 3H), 2.11 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 169.3, 163.5, 160.7, 128.7, 128.3, 127.8, 127.5, 126.8, 120.2, 113.2, 104.0, 54.4, 19.1. HRMS (ESI) (*m/z*): [M+H]⁺ calcd. for C₁₇H₁₆NO₂S: 298.0886, found: 298.0896.

5-(4-Fluorophenyl)-4-(methylthio)-3-phenylisoxazole(3d). White solid (90mg, 63%); mp 71-74 °C. IR(KBr) 3053, 2870, 1642, 1160, 1008cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.24-8.20 (m, 2H), 7.96-7.91 (m, 2H), 7.60-7.51 (m, 3H), 3.89 (s, 3H), 7.24-7.16 (m, 2H), 2.49 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 169.57-169.54(d, *J* 3Hz), 163.5, 161.8, 158.7, 130.6, 129.9, 129.8, 127.77-127.71(d, *J* 6Hz), 124.9, 122.0, 118.81-118.59(d, *J* 3Hz), 105.5, 17.4. ¹⁹F NMR (376 MHz, CDCl₃) δ -110.01. HRMS (ESI) (*m/z*): [M+H]⁺ calcd. for C₁₆H₁₃FNOS: 286.0674, found: 286.0696.

5-(4-Chlorophenyl)-4-(methylthio)-3-phenylisoxazole(3e).¹⁶ White solid (98mg, 65%); mp 80-83 °C. IR(KBr) 3037, 2954, 1646, 1153, 1087cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.16 (d, *J* 8.8 Hz, 2H), 8.00-7.97 (m, 2H), 7.54-7.49 (m, 5H), 2.11 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 166.9, 160.2, 138.1, 128.6, 128.4, 128.0, 127.7, 127.6, 126.7, 126.3, 109.7, 18.8. HRMS (ESI) (*m/z*): [M+H]⁺ calcd. for C₁₆H₁₃ClNOS: 302.0398, found: 302.0401.

5-(4-Bromophenyl)-4-(methylthio)-3-phenylisoxazole(3f). White solid (116mg, 67%); mp 84-87 °C. IR(KBr) 3028, 2866, 1620, 1158, 1025cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, *J* 8.7 Hz, 2H), 7.31 (d, *J* 8.5 Hz, 2H), 7.25-7.19 (m, 5H), 2.32 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.2, 168.5, 136.2, 130.4, 130.2, 128.8, 128.7, 127.4, 126.5, 125.7, 107.0, 18.3. HRMS (ESI) (*m/z*): [M+H]⁺ calcd. for C₁₆H₁₃BrNOS: 345.9901, found: 345.9896.

4-(Methylthio)-5-(4-nitrophenyl)-3-phenylisoxazole(3g). Light yellow solid (95mg, 61%); mp 87-90 °C. IR(KBr) 3050, 2961, 1627, 1179, 1012cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.42 (d, *J* 8.9 Hz, 2H), 8.15 (d, *J* 8.7 Hz, 2H), 7.99-7.95 (m, 2H), 7.58-7.50 (m, 3H), 2.45 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 162.9, 148.5, 130.6, 129.6, 128.9, 127.8, 125.9, 124.3, 107.1, 21.1. HRMS (ESI) (*m/z*): [M+H]⁺ calcd. for C₁₆H₁₃N₂O₃S: 313.0640, found: 313.0641.

5-(3-Chlorophenyl)-4-(methylthio)-3-phenylisoxazole(3h). White solid (93mg, 62%); mp 89-92 °C. IR(KBr) 3044, 2906, 1623, 1173, 782cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.07-8.03 (m, 2H), 7.97 (d, *J* 8.7 Hz, 2H), 7.58-7.49 (m, 5H), 2.44 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 167.5, 163.1, 147.4, 130.1, 129.6, 129.1, 127.8, 126.5, 125.9, 125.1, 124.4, 107.2, 20.0. HRMS (ESI) (*m/z*): [M+H]⁺ calcd. for C₁₆H₁₃ClNOS: 302.0409, found: 302.0401.

4-(Methylthio)-3-phenyl-5-(thiophen-2-yl)isoxazole(3i). Light yellow solid (74mg, 54%); mp =60-64 °C. IR(KBr)= 3102, 2892, 1632, 1171, 1026, 711 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 7.88 (d, *J* 3.7 Hz, 2H), 7.67-7.61 (m, 3H), 7.54-7.49 (m, 3H), 7.22 (dd, *J* 5.0, 3.8 Hz, 1H), 2.42 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ=164.4, 162.0, 130.1, 130.0, 129.3, 128.5, 127.9, 127.3, 127.1, 126.4, 104.1, 19.7. HRMS (ESI) (*m/z*): [M+H]⁺ calcd. for C₁₄H₁₂NOS₂: 274.0364, found: 274.0355.

5-(Furan-2-yl)-4-(methylthio)-3-phenylisoxazole(3j). Light yellow solid (72mg, 56%); mp 60-63 °C. IR(KBr) 3025, 2943, 1636, 1114, 1007, 742cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.82 (dd, *J* 1.7, 0.7 Hz, 1H), 7.65-7.62 (m, 2H), 7.53-7.49 (m, 3H), 7.30 (d, *J* 3.6 Hz, 1H), 6.65(dd, *J* 3.6, 1.8 Hz, 1H), 2.45 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.5, 161.3, 139.6, 135.2, 129.3, 127.9, 127.6, 126.2, 119.1, 114.4, 103.6, 15.9. HRMS (ESI) (*m/z*): [M+H]⁺ calcd. for C₁₄H₁₂NO₂S: 258.0589, found: 258.0583.

5-Methyl-4-(methylthio)-3-phenylisoxazole(3k). Yellow liquid (33mg, 32%). IR(KBr)= 3019, 2870, 1602, 1162, 1007cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =8.06(dd, *J* 7.7, 1.6 Hz, 2H), 7.51-7.44 (m, 3H), 2.61 (s, 3H), 2.46 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3) δ 168.7, 163.1, 132.1, 130.2, 129.0, 128.6, 107.4, 15.3, 12.4. HRMS (ESI) (m/z): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{11}\text{H}_{12}\text{NOS}$: 206.0630, found: 206.0634.

5-Butyl-4-(methylthio)-3-phenylisoxazole(3l). Yellow liquid (43mg, 35%). IR(KBr) 3043, 2930, 1616, 1173, 1010 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.01 (dd, J 8.0, 4.0 Hz, 2H), 7.51–7.48 (m, 3H), 2.90 (t, J 8.0 Hz, 2H), 2.11 (s, 3H), 1.80–1.70 (m, 2H), 1.46–1.35 (m, 2H), 0.89 (t, 3H, J 8.0 Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 161.5, 161.3, 139.6, 135.2, 129.3, 127.9, 127.6, 126.2, 119.1, 114.4, 103.6, 15.9. HRMS (ESI) (m/z): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{14}\text{H}_{18}\text{NOS}$: 248.1099, found: 248.1104.

4-(Methylthio)-5-phenyl-3-(*p*-tolyl)isoxazole(3m). White solid (103mg, 73%); mp 107–111 $^\circ\text{C}$. IR(KBr) 3061, 2922, 1634, 1177, 1025 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.10 (d, J 8.6 Hz, 2H), 7.66 (d, J 7.9 Hz, 2H), 7.62–7.60(m, 3H), 7.14 (d, J 7.9 Hz, 2H), 2.46 (s, 3H), 2.31 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.4, 163.6, 134.2, 131.5, 129.3, 128.7, 128.7, 127.5, 126.2, 124.6, 106.6, 21.4, 18.0. HRMS (ESI) (m/z): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{17}\text{H}_{16}\text{NOS}$: 282.0956, found: 282.0947.

3-(4-Methoxyphenyl)-4-(methylthio)-5-phenylisoxazole(3n). White solid (104mg, 70%); mp 77–81 $^\circ\text{C}$. IR(KBr) 3027, 2968, 1625, 1123, 1017, 824 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.14–8.10 (m, 2H), 7.95(d, J 8.7 Hz, 2H), 7.55–7.51 (m, 3H), 7.03 (d, J 8.9 Hz, 2H), 3.87 (s, 3H), 2.37 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ =168.5, 161.3, 160.6, 131.5, 130.2, 128.8, 126.2, 123.2, 120.6, 119.9, 106.5, 55.3, 15. HRMS (ESI) (m/z): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{17}\text{H}_{16}\text{NO}_2\text{S}$: 298.0902, found: 298.0896.

3-(4-Fluorophenyl)-4-(methylthio)-5-phenylisoxazole(3o). Light yellow solid (91mg, 64%); mp 86–89 $^\circ\text{C}$. IR(KBr) 3045, 2903, 1639, 1228, 1154, 1026 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.16–8.12 (m, 2H), 7.98 (dd, J 8.7, 5.3 Hz, 2H), 7.58–7.52 (m, 3H), 8.22–8.18 (m, 2H), 2.27 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.3, 162.6, 131.9, 130.7, 129.08, 128.0, 127.8, 127.7, 126.3, 105.1, 15.5. ^{19}F NMR (376 MHz, CDCl_3) δ -114.3. HRMS (ESI) (m/z): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{16}\text{H}_{13}\text{FNOS}$: 286.0690, found: 286.0696.

3-(4-Chlorophenyl)-4-(methylthio)-5-phenylisoxazole(3p). Light yellow solid (104mg, 69%); mp 72–74 $^\circ\text{C}$. IR(KBr) 3027, 2876, 1623, 1167, 1009 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.07–8.03 (m, 2H), 7.93(d, J 8.4 Hz, 2H), 7.52–7.41 (m, 5H), 2.37 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.3, 162.6, 131.9, 130.7, 129.1, 128.0, 127.8, 127.7, 126.3, 105.1, 15.5. HRMS (ESI) (m/z): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{16}\text{H}_{13}\text{ClNOS}$: 302.0395, found: 302.0401.

3-(4-Bromophenyl)-4-(methylthio)-5-phenylisoxazole(3q). White solid (121mg, 70%); mp 64–67 $^\circ\text{C}$. IR(KBr) 3041, 2967, 1625, 1168, 1012, 822 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.08–8.06 (m, 2H), 7.95 (d, J 8.6 Hz, 2H), 7.55–7.46 (m, 5H), 2.45 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.9, 162.4, 130.9, 130.7, 129.3, 127.8, 126.8, 125.5, 124.8, 124.0, 105.1, 15.6. HRMS (ESI) (m/z): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{16}\text{H}_{13}\text{BrNOS}$: 345.9890, found: 345.9896.

4-(Methylthio)-3-(4-nitrophenyl)-5-phenylisoxazole(3r). White solid (101mg, 65%); mp 104–106 $^\circ\text{C}$. IR(KBr) 3041, 2959, 1643, 1523, 1186, 1012, 844 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.40–8.38 (m, 2H), 8.11 (d, J 8.7 Hz, 2H), 8.01 (d, J 7.2 Hz, 2H), 7.62–7.53 (m, 3H), 2.11 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 166.2, 162.0, 147.4, 132.3, 129.6, 129.1, 1127.8, 126.5, 125.1, 122.9, 106.8, 15.7. HRMS (ESI) (m/z): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{16}\text{H}_{13}\text{N}_2\text{O}_3\text{S}$: 313.0635, found: 313.0641.

3-(4-(*tert*-Butyl)phenyl)-4-(methylthio)-5-phenylisoxazole(3s). White solid (110mg, 68%); mp 101–103 $^\circ\text{C}$. IR(KBr) 3057, 2906, 1609, 1388, 1162, 822 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ = 8.10 (d, J 8.6 Hz, 2H), 7.80 (d, J 8.6 Hz, 2H), 7.34–7.28 (m, 3H), 7.14 (d, J 7.2 Hz, 2H), 2.40 (s, 3H), 1.37 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.0, 165.6, 158.3, 130.6, 129.6, 128.5, 128.4, 127.1, 125.2, 125.0, 107.6, 35.4, 31.0, 15.6. HRMS (ESI) (m/z): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{20}\text{H}_{22}\text{NOS}$: 324.1424, found: 324.1417.

4-(Methylthio)-3-(naphthalen-2-yl)-5-phenylisoxazole(3t). Yellow liquid (106mg, 67%). IR(KBr) 3053, 2952, 1610, 1161, 1008, 805 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.49–8.45 (m, 1H), 7.90 (d, J 7.2 Hz, 2H), 7.84–7.82 (m, 1H), 7.80–7.73 (m, 2H), 7.70–7.64 (m, 1H), 7.55–7.49 (m, 5H), 2.45 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ

171.7, 169.5, 131.1, 129.5, 127.6, 125.9, 107.1, 33.4, 28.6, 19.1. HRMS (ESI) (m/z): $[M+H]^+$ calcd. for $C_{20}H_{16}NOS$: 318.0940, found: 318.0947.

4-(Methylthio)-5-phenyl-3-(thiophen-2-yl)isoxazole(3u). White solid (76mg, 56%); mp 66-68 °C. IR(KBr) 3107, 2963, 1628, 1174, 1003, 707 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 7.99 (d, J 7.3 Hz, 2H), 7.61–7.50 (m, 5H), 7.19 (dd, J 5.1, 3.7 Hz, 1H), 2.38 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ =169.6, 156.3, 130.2, 128.8, 127.9, 127.8, 127.7, 126.8, 126.4, 125.3, 104.5, 15.5. HRMS (ESI) (m/z): $[M+H]^+$ calcd. for $C_{14}H_{12}NOS_2$: 274.0355, found: 274.0355.

3-(tert-Butyl)-4-(methylthio)-5-phenylisoxazole(3v).¹⁶ Yellow liquid (59mg, 48%). IR(KBr) 3035, 2900, 1612, 1385, 1174, 1017 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 8.20 (d, 2H, J 7.6 Hz), 7.51-7.46 (m, 3H), 2.19 (s, 3H), 1.52 (s, 9H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 171.7, 169.5, 131.1, 129.5, 127.6, 125.9, 107.1, 33.4, 28.6, 19.1. HRMS (ESI) (m/z): $[M+H]^+$ calcd. for $C_{14}H_{18}NOS$: 248.1103, found: 248.1104.

4-(Methylthio)-3,5-di-p-tolylisoxazole(3w). White solid (108mg, 73%); mp 189-192 °C. IR(KBr) 3055, 2920, 2863, 1633, 1455, 1171, 1018 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 7.97 (d, J 8.1 Hz, 2H), 7.78 (d, J 8.1Hz, 2H), 7.35-7.28 (m, 4H), 2.45 (s, 3H), 2.44 (s, 3H), 2.33 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 168.7, 164.5, 139.1, 137.4, 129.5, 129.3, 128.6, 125.9, 124.0, 123.8, 106.1, 22.1, 22.0, 19.5. HRMS (ESI) (m/z): $[M+H]^+$ calcd. for $C_{18}H_{18}NOS$: 296.1110, found: 296.1104.

3,5-Bis(4-methoxyphenyl)-4-(methylthio)isoxazole(3x). White solid (121mg, 74%); mp 116-119 °C. IR(KBr) 3057, 2933, 1629, 1488, 1167, 1025, 828 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 8.13 (d, J 8.1 Hz, 2H), 7.71 (d, J 8.7Hz, 2H), 7.05–7.00 (m, 4H), 3.87 (s, 3H), 3.86 (s, 3H), 2.44 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 170.2, 163.3, 162.1, 130.3, 130.0, 127.4, 124.8, 121.0, 119.0, 115.0, 105.2, 55.7, 55.6, 21.4. HRMS (ESI) (m/z): $[M+H]^+$ calcd. for $C_{18}H_{18}NO_3S$: 328.1011, found: 328.1002.

Acknowledgements

We are grateful to Fuzhou University Zhicheng College College Students' Innovation and Entrepreneurship Training Program (2025045) for the support of this work.

Supplementary Material

Supplementary material is available on the publisher's website along with the published article.

References

1. Zhu, J.; Mo, J.; Lin, H.-Z.; Chen, Y.; Sun, H.-P. *Bioorg. Med. Chem.* **2018**, *26*, 3065. <https://doi.org/10.1016/j.bmc.2018.05.013>
2. Hu, F.; Szostak, M. *Adv. Synth. Catal.* **2015**, *357*, 2583. <https://doi.org/10.1002/adsc.201500319>
3. Li, L.; Tan, T.-D.; Zhang, Y.-Q.; Liu, X.; Ye, L.-W. *Org. Biomol. Chem.* **2017**, *15*, 8483. <https://doi.org/10.1039/C7OB01895A>
4. Ilardi, E. A.; Vitaku, E.; Njardarson, J. T. *J. Med. Chem.* **2014**, *57*, 2832. <https://doi.org/10.1021/jm401375q>

5. Minghao, F.; Bingqing, T.; Steven, H. L.; Xuefeng, J. *Curr. Top. Med. Chem.* **2016**, *16*, 1200.
<https://doi.org/10.1021/jm501853m>
6. Beno, B. R.; Yeung, K.-S.; Bartberger, M. D.; Pennington, L. D.; Meanwell, N. A. *J. Med. Chem.* **2015**, *58*, 4383.
7. Morita, T.; Yugandar, S.; Fuse, S.; Nakamura, H. *Tetrahedron Lett.* **2018**, *59*, 1159.
<https://doi.org/10.1016/j.tetlet.2018.02.020>
8. Kanda, Y.; Takahashi, T.; Araki, Y.; Konoike, T.; Mihara, S.-I.; Fujimoto, M. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 1875.
[https://doi.org/10.1016/S0960-894X\(00\)00366-8](https://doi.org/10.1016/S0960-894X(00)00366-8)
9. Morita, T.; Fuse, S.; Nakamura, H. *Angew. Chem. Int. Ed.* **2016**, *55*, 13580.
<https://doi.org/10.1002/anie.201608039>
10. Waldo, J. P.; Larock, R. C. *Org. Lett.* **2005**, *7*, 5203.
<https://doi.org/10.1021/ol052027z>
11. Waldo, J. P.; Larock, R. C. *J. Org. Chem.* **2007**, *72*, 9643.
<https://doi.org/10.1021/jo701942e>
12. Kaewsri, W.; Thongsornkleeb, C.; Tummatorn, J.; Ruchirawat, S. *RSC Adv.* **2016**, *6*, 48666.
<https://doi.org/10.1039/C6RA09396E>
13. Jeong, Y.; Kim, B.-I.; Lee, J. K.; Ryu, J.-S. *J. Org. Chem.* **2014**, *79*, 6444.
<https://doi.org/10.1021/jo5008702>
14. Sperança, A.; Godoi, B.; Zeni, G. *J. Org. Chem.* **2013**, *78*, 1630.
<https://doi.org/10.1021/jo302770g>
15. Tu, K. N.; Hirner, J. J.; Blum, S. A. *Org. Lett.* **2016**, *18*, 480.
<https://doi.org/10.1021/acs.orglett.5b03530>
16. Gao, W.-C.; Cheng, Y.-F.; Chang, H.-H.; Li, X.; Wei, W.-L.; Yang, P. *J. Org. Chem.* **2019**, *84*, 4312.
<https://doi.org/10.1021/acs.joc.9b00256>
17. Helmkamp, G. K.; Olsen, B. A.; Pettitt, D. J. *J. Org. Chem.* **1965**, *30*, 676.
<https://doi.org/10.1021/jo01014a003>
18. Smallcombe, S. H.; Caserio, M. C. *J. Am. Chem. Soc.* **1971**, *93*, 5826.
<https://doi.org/10.1021/ja00751a041>
19. Anderson, S. A.; Kim, J. K.; Caserio, M. C. *J. Org. Chem.* **1978**, *43*, 4822.
<https://doi.org/10.1021/jo00419a023>
20. Minato, H.; Miura, T.; Kobayashi, M. *Chem. Lett.* **1975**, *4*, 701.
<https://doi.org/10.1246/cl.1975.701>
21. O'Malley, G. J.; Cava, M. P. *Tetrahedron Lett.* **1985**, *26*, 6159.
[https://doi.org/10.1016/S0040-4039\(00\)95041-X](https://doi.org/10.1016/S0040-4039(00)95041-X)
22. Okuma, K.; Yasuda, T.; Takeshita, I.; Shioji, K.; Yokomori, Y. *Tetrahedron* **2007**, *63*, 8250.
<https://doi.org/10.1016/j.tet.2007.05.111>
23. Okuma, K.; Takeshita, I.; Yasuda, T.; Shioji, K. *Chem. Lett.* **2006**, *35*, 1122.
<https://doi.org/10.1246/cl.2006.1122>
24. Amat, M.; Alvarez, M.; Bonjoch, J.; Casamitjana, N.; Gràcia, J.; Lavilla, R.; Garcías, X.; Bosch, J. *Tetrahedron Lett.* **1990**, *31*, 3453.
[https://doi.org/10.1016/S0040-4039\(00\)97420-3](https://doi.org/10.1016/S0040-4039(00)97420-3)

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)